Technical Description
The invention relates to active fraction from a kiwi fruit (Actinidia)extarct, where the size of the molecules in the active fraction being less than 1000 daltons characterized as being stable and retaining inhibition of platelet aggregation angiotensin converting enzyme activity and further improving or maintaining cardiovascular health. This kiwi fruit extract when consumed is expected to improve blood flow and lower blood pressure, the important risk factors for heart disease. The fraction of the present invention may be incorporated in dietary supplement, formulated with pharmaceutical carriers such as starch, sucrose or lactose in tablets, pills, capsules, etc., syrups or food stuff. The invention further relates to method of producing a stable and biologically active Actinidia extract fraction comprising the steps of producing an Actinidia extract; heating the Actinidia extract to 70 to 100 degree celsius for more than five minutes so that the extract retains biological activity during storage; and processing the extract by ultrafiltration either before or after heating.
Tech Features
- Inhibits platelet aggregation thus improves blood flow and blood thinning.
- Inhibits angiotensin converting enzyme thus lowers blood pressure.
- An active fraction with an enhanced shelf-life of at least 1 year at 4 degrees Celsius.
- No side effects.
